CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML

CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML

FLT3‐ITD tyrosine kinase inhibitors (TKI) show limited clinical activity in acute myeloid leukemia (AML) due to emerging resistance. TKI resistance is mediated by secondary FLT3‐ITD mutations only in a minority of cases. We hypothesize that the cytokine CCL5 protects AML cells from TKI‐mediated cell...

Full description

Bibliographic Details
Main Authors: Silvia Waldeck, Michael Rassner, Philip Keye, Marie Follo, Dieter Herchenbach, Cornelia Endres, Anne Charlet, Geoffroy Andrieux, Ulrich Salzer, Melanie Boerries, Justus Duyster, Nikolas vonBubnoff
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:Molecular Oncology
Subjects:
CCL5/RANTES
FLT3‐ITD
PKC412
TKI resistance
Online Access:https://doi.org/10.1002/1878-0261.12640

Internet

https://doi.org/10.1002/1878-0261.12640

Similar Items